The industry's main trade group is challenging the government's push to tie US drug prices to those paid abroad, a policy projected to save $64.3B over 10 years

The Danish drugmaker's US price cut for its obesity drug marks a broadening price battle among GLP-1 makers facing political and competitive pressure.

The lawsuit targets telehealth sales of compounded semaglutide, tightening Novo's defense of its obesity franchise as rivals market cheaper alternatives.

India's cap on cancer drug trade margins is expected to cut prices 20-70%, with industry bodies backing it while flagging affordability and sustainability conce

The approval extends Tecentriq to stage III dMMR colon cancer after a trial showed adding the immune drug to chemo cut recurrence or death risk 50%.

The long-acting injectable offers schizophrenia patients a monthly subcutaneous option without added pills or post-injection monitoring.

The retreat from the obesity drug race is a setback for Pfizer in the highly competitive GLP-1 market.

Investor anticipation builds around the first-ever Phase 3 data for an in vivo gene-editing therapy, a milestone for the CRISPR field.

A positive late-stage readout for the depression drug candidate sent shares sharply higher premarket, a notable win in a difficult CNS category.

Regulatory moves paving the way for cheaper GLP-1 alternatives could reshape pricing and access in the obesity drug market.

The designation could speed review of a blood-based screening test meant to detect multiple cancers, a fast-growing diagnostics segment.

An overwhelmingly positive advisory panel readout raised analyst expectations for Replimune's melanoma therapy ahead of an FDA decision.

The trial results reinforce Novo's clinical evidence base as it faces mounting competition in the obesity market.

Investor caution returns to the GLP-1 space as competition, pricing pressure and pipeline setbacks temper earlier enthusiasm.

The investment bank's disclosure of a sizable stake across three small-cap biotechs highlights institutional interest before near-term clinical and regulatory e

Review documents and subgroup data add uncertainty to Revolution Medicines' closely watched KRAS program.

Korean competition in obesity drugs intensifies around price, potency and convenience as new entrants challenge established GLP-1 brands.

The approval adds a new therapy to Novartis's portfolio, though analysts remain cautious with the stock rated Hold.